Replies to post #420461 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

How? It’s the easier of the two trials

Agree. There will be many months between getting the EXCELLENCE top line results and the filing of an NDA. The shorts have ruled AVXL for quite a while, and they must be comfortable that they can deal with whatever temporary price bump results from an announcement of initial successful Rett top line data. Further, the shorts are not up against any near-term timeline that threatens them with regard to the AD indication. It looks to me like the shorts can continue to ride high in the saddle through 2023 unless there is a surprise unexpected favorable news development. Hopefully, 2024 will be quite a different story.